(Reuters) -Rhythm Pharmaceuticals said on Friday the U.S. Food and Drug Administration has extended the review period for expanded approval of its drug, Imcivree, as a treatment for a rare form of obesity.
(Reporting by Sneha S K; Editing by Sahal Muhammed)
Brought to you by www.srnnews.com
